Percutaneous Transcatheter Hepatic Artery Embolization for Liver Cysts in Autosomal Dominant Polycystic Kidney Disease

Takei, Ryoji; Ubara, Yoshifumi; Hoshino, Junichi; Higa, Yasushi; Suwabe, Tatsuya; Sogawa, Yoko; Nomura, Kazufumi; Nakanishi, Shohei; Sawa, Naoki; Katori, Hideyuki; Takemoto, Fumi; Hara, Shigeko; Takaichi, Kenmei

doi:10.1053/j.ajkd.2007.03.018

Cited by 71 publications

(63 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Complications are uncommon and include bleeding, rupture and infection of cysts [31] . The most severe complication is bacterial infection, especially those under dialysis for ADPKD or in immunosuppressed patients after renal transplantation [32][33][34][35][36][37] . This is usually managed with aspiration and drainage, and antibiotics.…”

Section: Pcldmentioning

confidence: 99%

Current management of noninfectious hepatic cystic lesions: A review of the literature

Macedo¹

2013

WJH

View full text Add to dashboard Cite

Nonparasitic hepatic cysts consist of a heterogeneous group of disorders, which differ in etiology, prevalence, and manifestations. With improving diagnostic techniques, hepatic cysts are becoming more common. Recent advancements in minimally invasive technology created a new Era in the management of hepatic cystic disease. Herein, the most current recommendations for management of noninfectious hepatic cysts are described, thereby discussing differential diagnosis, new therapeutic modalities and outcomes. Key words: simple hepatic cyst; Noninfectious; Polycystic liver disease; Cystadenoma; Cystadenocarcinoma; Caroli's disease; sclerotherapy; Fenestration Core tip: Nonparasitic hepatic cysts consist of a broad spectrum of entities ranging from benign developmental cysts to malignant neoplasms. With recent advancements in diagnostic studies, hepatic cysts are becoming more frequent and better understanding of risk factors, management and long-term outcomes, and further development of current therapeutic modalities are needed.

show abstract

Section: Pcldmentioning

confidence: 99%

Current management of noninfectious hepatic cystic lesions: A review of the literature

Macedo¹

2013

WJH

View full text Add to dashboard Cite

show abstract

“…4,5 Percutaneous treatments, such as cyst drainage, are less invasive than surgical resection and have become a mainstay of treatment; however, in cases of PCLD where numerous small cysts have accumulated (as in the present case) drainage is ineffective in alleviating symptoms. 6 Transcatheter arterial embolization, which makes it possible to reduce the size of the liver overall, is generally used in most clinics and hospitals.…”

Section: Discussionmentioning

confidence: 84%

“…6 Transcatheter arterial embolization, which makes it possible to reduce the size of the liver overall, is generally used in most clinics and hospitals. 5 A coil or a liquid embolic material, such as NBCA, has been used as the embolic materials, but the use of a coil alone may result in proximal embolization and fail to achieve adequate reduction in liver size. 7 N-butyl cyanoacrylate, on the other hand, allows adequate embolization as far as the periphery.…”

Section: Discussionmentioning

confidence: 99%

“…After embolization of the hepatic artery, symptoms of post-TAE syndrome, including fever and pain, sometimes occurs, but is always minor, and can often be addressed with medical treatment. 5,8 Placement of an indwelling IVC stent also does not typically result in severe complications. 2 Therefore, we implemented both treatments simultaneously and achieved rapid relief of symptoms without any apparent complications.…”

Section: Discussionmentioning

confidence: 99%

“…3 In such cases, surgical resection or interventional procedure (eg, transcatheter arterial embolization [TAE]) can be implemented to alleviate symptoms. 4,5 A self-expandable metallic stent also has been used (although not greatly) for inferior vena cava syndrome. 2 However, to the extent that we searched, we found no reports where TAE and IVC stenting had been implemented simultaneously in the same patient.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Untitled

Fujita

Tanabe²,

Uchiyama³

et al. 2014

Exp Clin Transplant

View full text Add to dashboard Cite

Autosomal-dominant polycystic kidney disease is frequently complicated by polycystic liver disease. Some patients with polycystic liver disease have a full-stomach sensation and intractable ascites. We report a 56-year-old woman with polycystic liver disease waiting to receive a liver transplant, with a chief complaint of a full-stomach sensation and refractory ascites, wherein the transcatheter hepatic arterial embolization and inferior vena cava stenting were begun simultaneously, and the signs were favorably alleviated.It is important to recognize the risk of liver failure after the complete embolization of both the right and left hepatic arteries; however, performance of transcatheter hepatic arterial embolization and inferior vena cava stent placement also are indicated for patients awaiting a liver transplant for early alleviation of symptoms.

show abstract

Polycystic Kidney Disease

Ghata

Cowley

2017

Comprehensive Physiology

View full text Add to dashboard Cite

Renal cysts, which arise from renal tubules, can be seen in a variety of hereditary and nonhereditary entities. Common mechanisms associated with renal cyst formation include increased cell proliferation, epithelial fluid secretion, and extracellular matrix remodeling. Hereditary polycystic kidney disease (PKD) is seen as a component of numerous diseases. Autosomal dominant (AD) PKD is the most common potentially fatal hereditary disease in humans, causes renal failure in approximately 50% of affected individuals, and accounts for approximately 5% of end stage renal disease cases in the United States. ADPKD is caused by mutation in one of two genes-85% of cases are caused by mutation in PKD1 on chromosome 16 and 15% of cases are caused by mutation in PKD2 on chromosome 4. Polycystin-1, encoded by PKD1, is a large protein, has multiple transmembrane spanning domains, has extracellular regions suggesting a role in cell-cell or cell-matrix interactions, has intracellular domains suggesting a role in signal transduction, and can physically interact with Polycystin-2. Polycystin-2 is smaller, has transmembrane domains, can act as a cation channel with calcium permeability, and may be regulated by Polycystin-1. These proteins, and many others associated with cystic kidney disease, localize to primary cilia, which may act as flow sensors in the kidney; cystic kidney diseases have also been termed ciliopathies. An increasing number of intracellular mechanisms, which are abnormally regulated in PKD, have been described and are potential targets for therapy, which is lacking in this common hereditary disease. © 2017 American Physiological Society. Compr Physiol 7:945-975, 2017.

show abstract

Percutaneous Transcatheter Hepatic Artery Embolization for Liver Cysts in Autosomal Dominant Polycystic Kidney Disease

Cited by 71 publications

References 10 publications

Current management of noninfectious hepatic cystic lesions: A review of the literature

Current management of noninfectious hepatic cystic lesions: A review of the literature

Untitled

Polycystic Kidney Disease

Contact Info

Product

Resources

About